Copyright Reports & Markets. All rights reserved.

Global Respiratory Syncytial Virus Vaccines Market Insights, Forecast to 2028

Request for Sample of this report
Buy now

Table of Contents

    1 Report Business Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
      • 1.2.1 Global Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
      • 1.2.2 Palivizumab
      • 1.2.3 RSVpreF PF06928316
      • 1.2.4 RSVPreF3 OA (GSK3844766A)
      • 1.2.5 mRNA-1345
      • 1.2.6 Janssen RSV Vaccine
      • 1.2.7 ResVax
      • 1.2.8 Nirsevimab (MEDI8897)
      • 1.2.9 MVA-BN RSV
    • 1.3 Market by Application
      • 1.3.1 Global Respiratory Syncytial Virus Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
      • 1.3.2 Hospital
      • 1.3.3 Clinic
      • 1.3.4 Research Institute
    • 1.4 Study Objectives
    • 1.5 Years Considered

    2 Global Growth Trends

    • 2.1 Global Respiratory Syncytial Virus Vaccines Market Perspective (2017-2028)
    • 2.2 Respiratory Syncytial Virus Vaccines Growth Trends by Region
      • 2.2.1 Respiratory Syncytial Virus Vaccines Market Size by Region: 2017 VS 2021 VS 2028
      • 2.2.2 Respiratory Syncytial Virus Vaccines Historic Market Size by Region (2017-2022)
      • 2.2.3 Respiratory Syncytial Virus Vaccines Forecasted Market Size by Region (2023-2028)
    • 2.3 Respiratory Syncytial Virus Vaccines Market Dynamics
      • 2.3.1 Respiratory Syncytial Virus Vaccines Industry Trends
      • 2.3.2 Respiratory Syncytial Virus Vaccines Market Drivers
      • 2.3.3 Respiratory Syncytial Virus Vaccines Market Challenges
      • 2.3.4 Respiratory Syncytial Virus Vaccines Market Restraints

    3 Competition Landscape by Key Players

    • 3.1 Global Top Respiratory Syncytial Virus Vaccines Players by Revenue
      • 3.1.1 Global Top Respiratory Syncytial Virus Vaccines Players by Revenue (2017-2022)
      • 3.1.2 Global Respiratory Syncytial Virus Vaccines Revenue Market Share by Players (2017-2022)
    • 3.2 Global Respiratory Syncytial Virus Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.3 Players Covered: Ranking by Respiratory Syncytial Virus Vaccines Revenue
    • 3.4 Global Respiratory Syncytial Virus Vaccines Market Concentration Ratio
      • 3.4.1 Global Respiratory Syncytial Virus Vaccines Market Concentration Ratio (CR5 and HHI)
      • 3.4.2 Global Top 10 and Top 5 Companies by Respiratory Syncytial Virus Vaccines Revenue in 2021
    • 3.5 Respiratory Syncytial Virus Vaccines Key Players Head office and Area Served
    • 3.6 Key Players Respiratory Syncytial Virus Vaccines Product Solution and Service
    • 3.7 Date of Enter into Respiratory Syncytial Virus Vaccines Market
    • 3.8 Mergers & Acquisitions, Expansion Plans

    4 Respiratory Syncytial Virus Vaccines Breakdown Data by Type

    • 4.1 Global Respiratory Syncytial Virus Vaccines Historic Market Size by Type (2017-2022)
    • 4.2 Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Type (2023-2028)

    5 Respiratory Syncytial Virus Vaccines Breakdown Data by Application

    • 5.1 Global Respiratory Syncytial Virus Vaccines Historic Market Size by Application (2017-2022)
    • 5.2 Global Respiratory Syncytial Virus Vaccines Forecasted Market Size by Application (2023-2028)

    6 North America

    • 6.1 North America Respiratory Syncytial Virus Vaccines Market Size (2017-2028)
    • 6.2 North America Respiratory Syncytial Virus Vaccines Market Size by Type
      • 6.2.1 North America Respiratory Syncytial Virus Vaccines Market Size by Type (2017-2022)
      • 6.2.2 North America Respiratory Syncytial Virus Vaccines Market Size by Type (2023-2028)
      • 6.2.3 North America Respiratory Syncytial Virus Vaccines Market Share by Type (2017-2028)
    • 6.3 North America Respiratory Syncytial Virus Vaccines Market Size by Application
      • 6.3.1 North America Respiratory Syncytial Virus Vaccines Market Size by Application (2017-2022)
      • 6.3.2 North America Respiratory Syncytial Virus Vaccines Market Size by Application (2023-2028)
      • 6.3.3 North America Respiratory Syncytial Virus Vaccines Market Share by Application (2017-2028)
    • 6.4 North America Respiratory Syncytial Virus Vaccines Market Size by Country
      • 6.4.1 North America Respiratory Syncytial Virus Vaccines Market Size by Country (2017-2022)
      • 6.4.2 North America Respiratory Syncytial Virus Vaccines Market Size by Country (2023-2028)
      • 6.4.3 United States
      • 6.4.4 Canada

    7 Europe

    • 7.1 Europe Respiratory Syncytial Virus Vaccines Market Size (2017-2028)
    • 7.2 Europe Respiratory Syncytial Virus Vaccines Market Size by Type
      • 7.2.1 Europe Respiratory Syncytial Virus Vaccines Market Size by Type (2017-2022)
      • 7.2.2 Europe Respiratory Syncytial Virus Vaccines Market Size by Type (2023-2028)
      • 7.2.3 Europe Respiratory Syncytial Virus Vaccines Market Share by Type (2017-2028)
    • 7.3 Europe Respiratory Syncytial Virus Vaccines Market Size by Application
      • 7.3.1 Europe Respiratory Syncytial Virus Vaccines Market Size by Application (2017-2022)
      • 7.3.2 Europe Respiratory Syncytial Virus Vaccines Market Size by Application (2023-2028)
      • 7.3.3 Europe Respiratory Syncytial Virus Vaccines Market Share by Application (2017-2028)
    • 7.4 Europe Respiratory Syncytial Virus Vaccines Market Size by Country
      • 7.4.1 Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2017-2022)
      • 7.4.2 Europe Respiratory Syncytial Virus Vaccines Market Size by Country (2023-2028)
      • 7.4.3 Germany
      • 7.4.4 France
      • 7.4.5 U.K.
      • 7.4.6 Italy
      • 7.4.7 Russia
      • 7.4.8 Nordic Countries

    8 Asia-Pacific

    • 8.1 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size (2017-2028)
    • 8.2 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Type
      • 8.2.1 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Type (2017-2022)
      • 8.2.2 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Type (2023-2028)
      • 8.2.3 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Share by Type (2017-2028)
    • 8.3 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Application
      • 8.3.1 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Application (2017-2022)
      • 8.3.2 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Application (2023-2028)
      • 8.3.3 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Share by Application (2017-2028)
    • 8.4 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region
      • 8.4.1 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2017-2022)
      • 8.4.2 Asia-Pacific Respiratory Syncytial Virus Vaccines Market Size by Region (2023-2028)
      • 8.4.3 China
      • 8.4.4 Japan
      • 8.4.5 South Korea
      • 8.4.6 Southeast Asia
      • 8.4.7 India
      • 8.4.8 Australia

    9 Latin America

    • 9.1 Latin America Respiratory Syncytial Virus Vaccines Market Size (2017-2028)
    • 9.2 Latin America Respiratory Syncytial Virus Vaccines Market Size by Type
      • 9.2.1 Latin America Respiratory Syncytial Virus Vaccines Market Size by Type (2017-2022)
      • 9.2.2 Latin America Respiratory Syncytial Virus Vaccines Market Size by Type (2023-2028)
      • 9.2.3 Latin America Respiratory Syncytial Virus Vaccines Market Share by Type (2017-2028)
    • 9.3 Latin America Respiratory Syncytial Virus Vaccines Market Size by Application
      • 9.3.1 Latin America Respiratory Syncytial Virus Vaccines Market Size by Application (2017-2022)
      • 9.3.2 Latin America Respiratory Syncytial Virus Vaccines Market Size by Application (2023-2028)
      • 9.3.3 Latin America Respiratory Syncytial Virus Vaccines Market Share by Application (2017-2028)
    • 9.4 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country
      • 9.4.1 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2017-2022)
      • 9.4.2 Latin America Respiratory Syncytial Virus Vaccines Market Size by Country (2023-2028)
      • 9.4.3 Mexico
      • 9.4.4 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size (2017-2028)
    • 10.2 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Type
      • 10.2.1 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Type (2017-2022)
      • 10.2.2 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Type (2023-2028)
      • 10.2.3 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Share by Type (2017-2028)
    • 10.3 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Application
      • 10.3.1 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Application (2017-2022)
      • 10.3.2 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Application (2023-2028)
      • 10.3.3 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Share by Application (2017-2028)
    • 10.4 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country
      • 10.4.1 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2017-2022)
      • 10.4.2 Middle East & Africa Respiratory Syncytial Virus Vaccines Market Size by Country (2023-2028)
      • 10.4.3 Turkey
      • 10.4.4 Saudi Arabia
      • 10.4.5 UAE

    11 Key Players Profiles

    • 11.1 Pfizer Inc.Pfizer Inc.
      • 11.1.1 Pfizer Inc.Pfizer Inc. Company Details
      • 11.1.2 Pfizer Inc.Pfizer Inc. Business Overview
      • 11.1.3 Pfizer Inc.Pfizer Inc. Respiratory Syncytial Virus Vaccines Introduction
      • 11.1.4 Pfizer Inc.Pfizer Inc. Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.1.5 Pfizer Inc.Pfizer Inc. Recent Developments
    • 11.2 Sanofi
      • 11.2.1 Sanofi Company Details
      • 11.2.2 Sanofi Business Overview
      • 11.2.3 Sanofi Respiratory Syncytial Virus Vaccines Introduction
      • 11.2.4 Sanofi Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.2.5 Sanofi Recent Developments
    • 11.3 Merck Sharp & Dohme
      • 11.3.1 Merck Sharp & Dohme Company Details
      • 11.3.2 Merck Sharp & Dohme Business Overview
      • 11.3.3 Merck Sharp & Dohme Respiratory Syncytial Virus Vaccines Introduction
      • 11.3.4 Merck Sharp & Dohme Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.3.5 Merck Sharp & Dohme Recent Developments
    • 11.4 GlaxoSmithKline
      • 11.4.1 GlaxoSmithKline Company Details
      • 11.4.2 GlaxoSmithKline Business Overview
      • 11.4.3 GlaxoSmithKline Respiratory Syncytial Virus Vaccines Introduction
      • 11.4.4 GlaxoSmithKline Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.4.5 GlaxoSmithKline Recent Developments
    • 11.5 SOBI
      • 11.5.1 SOBI Company Details
      • 11.5.2 SOBI Business Overview
      • 11.5.3 SOBI Respiratory Syncytial Virus Vaccines Introduction
      • 11.5.4 SOBI Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.5.5 SOBI Recent Developments
    • 11.6 Johnson & Johnson
      • 11.6.1 Johnson & Johnson Company Details
      • 11.6.2 Johnson & Johnson Business Overview
      • 11.6.3 Johnson & Johnson Respiratory Syncytial Virus Vaccines Introduction
      • 11.6.4 Johnson & Johnson Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.6.5 Johnson & Johnson Recent Developments
    • 11.7 Bavarian Nordic
      • 11.7.1 Bavarian Nordic Company Details
      • 11.7.2 Bavarian Nordic Business Overview
      • 11.7.3 Bavarian Nordic Respiratory Syncytial Virus Vaccines Introduction
      • 11.7.4 Bavarian Nordic Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.7.5 Bavarian Nordic Recent Developments
    • 11.8 Novavax
      • 11.8.1 Novavax Company Details
      • 11.8.2 Novavax Business Overview
      • 11.8.3 Novavax Respiratory Syncytial Virus Vaccines Introduction
      • 11.8.4 Novavax Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.8.5 Novavax Recent Developments
    • 11.9 AstraZeneca
      • 11.9.1 AstraZeneca Company Details
      • 11.9.2 AstraZeneca Business Overview
      • 11.9.3 AstraZeneca Respiratory Syncytial Virus Vaccines Introduction
      • 11.9.4 AstraZeneca Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.9.5 AstraZeneca Recent Developments
    • 11.10 Moderna
      • 11.10.1 Moderna Company Details
      • 11.10.2 Moderna Business Overview
      • 11.10.3 Moderna Respiratory Syncytial Virus Vaccines Introduction
      • 11.10.4 Moderna Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.10.5 Moderna Recent Developments
    • 11.11 Codagenix
      • 11.11.1 Codagenix Company Details
      • 11.11.2 Codagenix Business Overview
      • 11.11.3 Codagenix Respiratory Syncytial Virus Vaccines Introduction
      • 11.11.4 Codagenix Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.11.5 Codagenix Recent Developments
    • 11.12 Intravacc
      • 11.12.1 Intravacc Company Details
      • 11.12.2 Intravacc Business Overview
      • 11.12.3 Intravacc Respiratory Syncytial Virus Vaccines Introduction
      • 11.12.4 Intravacc Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.12.5 Intravacc Recent Developments
    • 11.13 Alphavax
      • 11.13.1 Alphavax Company Details
      • 11.13.2 Alphavax Business Overview
      • 11.13.3 Alphavax Respiratory Syncytial Virus Vaccines Introduction
      • 11.13.4 Alphavax Revenue in Respiratory Syncytial Virus Vaccines Business (2017-2022)
      • 11.13.5 Alphavax Recent Developments

    12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
        • 13.1.2 Data Source
      • 13.2 Author Details

      Summary:

      Market Analysis and Insights: Global Respiratory Syncytial Virus Vaccines Market
      The global Respiratory Syncytial Virus Vaccines market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
      Fully considering the economic change by this health crisis, Palivizumab accounting for % of the Respiratory Syncytial Virus Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
      China Respiratory Syncytial Virus Vaccines market size is valued at US$ million in 2021, while the North America and Europe Respiratory Syncytial Virus Vaccines are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Respiratory Syncytial Virus Vaccines landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
      With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Respiratory Syncytial Virus Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Respiratory Syncytial Virus Vaccines market in terms of revenue.
      Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Respiratory Syncytial Virus Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Respiratory Syncytial Virus Vaccines market.
      Impact of Covid-19 Outbreak
      This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
      Segmental Analysis
      The report has been segmented into product and application segments. The researchers have documented all the products present today in the Respiratory Syncytial Virus Vaccines market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
      Respiratory Syncytial Virus Vaccines Breakdown Data by Type
      Palivizumab
      RSVpreF PF06928316
      RSVPreF3 OA (GSK3844766A)
      mRNA-1345
      Janssen RSV Vaccine
      ResVax
      Nirsevimab (MEDI8897)
      MVA-BN RSV
      Respiratory Syncytial Virus Vaccines Breakdown Data by Application
      Hospital
      Clinic
      Research Institute
      By Region
      North America
      United States
      Canada
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Nordic Countries
      Rest of Europe
      Asia-Pacific
      China
      Japan
      South Korea
      Southeast Asia
      India
      Australia
      Rest of Asia
      Latin America
      Mexico
      Brazil
      Rest of Latin America
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Rest of MEA
      Competitive Landscape
      This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
      Pfizer Inc.Pfizer Inc.
      Sanofi
      Merck Sharp & Dohme
      GlaxoSmithKline
      SOBI
      Johnson & Johnson
      Bavarian Nordic
      Novavax
      AstraZeneca
      Moderna
      Codagenix
      Intravacc
      Alphavax
      Frequently Asked Questions
      What factors will challenge the Respiratory Syncytial Virus Vaccines market growth?
      Which end-use segment will expand at the fastest CAGR in the Respiratory Syncytial Virus Vaccines market?
      Which are the emerging players in the Respiratory Syncytial Virus Vaccines market?
      How concentrated is the Respiratory Syncytial Virus Vaccines market?
      Which factors are positively contributing to the Respiratory Syncytial Virus Vaccines market growth?
      Which are the novel product innovations in the Respiratory Syncytial Virus Vaccines market?
      Which product segment will emerge as the most lucrative in the Respiratory Syncytial Virus Vaccines market?
      Which factors are increasing the competition in the Respiratory Syncytial Virus Vaccines market?
      Which are the strategic measures taken by the Respiratory Syncytial Virus Vaccines industry players?
      Which region will witness inactive growth during the forecast period?
      What key trends are likely to emerge in the Respiratory Syncytial Virus Vaccines market in the coming years?
      Buy now